Mikhail Grubman at the “Right to Health” congress: We all share in the common cause...
Today, the issue of the national pharmaceutical industry development is more challenging than ever. Several factors are overlapped at once: both the 2020-2021 pandemic, and the 2022 events. Now we are talking not only about import substitution, but also about technological sovereignty in general. The experts discussed how pharmaceutical companies are coping with the challenges at the session "Nation building: development of import substitution" at the congress "Right to Health" on October 20.
Mikhail Grubman, managing director of Petrovax biotechnology business, spoke about how today's realities affect the work of a pharmaceutical company.
However, like other companies today, Petrovax faces certain challenges.
Our country is not the first to find itself in such a situation. Russian business today is adopting the experience of China and Iran, which have learned to overcome restrictions. Now Petrovax is making more and more deals with Eastern partners.
Today, the state and manufacturers are in their efforts to build an independent healthcare system quickly and efficiently. But first of all, it is important not to forget about the patient-oriented approach, in which the market players must cooperate to provide patients with the modern technologies.
